European Union - English - EMA (European Medicines Agency)

uniqure biopharma b.v.  - alipogene tiparvovec - hyperlipoproteinemia type i - lipid modifying agents - glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (lpld) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. the diagnosis of lpld has to be confirmed by genetic testing. the indication is restricted to patients with detectable levels of lpl protein.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - talimogene laherparepvec -

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - talimogene laherparepvec -

United States - English - NLM (National Library of Medicine)

amgen inc - talimogene laherparepvec (unii: 07730v90l6) (talimogene laherparepvec - unii:07730v90l6) - talimogene laherparepvec 1000000 [pfu] in 1 ml - imlygic is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. limitations of use : imlygic has not been shown to improve overall survival or have an effect on visceral metastases. imlygic is a live, attenuated herpes simplex virus and may cause life-threatening disseminated herpetic infection in patients who are immunocompromised. do not administer imlygic to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, aids or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy [see nonclinical toxicology ( 13.2 )] . do not administer imlygic to pregnant patients. risk summary adequate and well-controlled studies with imlygic have not been conducted in pregnant women. no effects on embryo-fetal development have been observed in a stu

United States - English - NLM (National Library of Medicine)

penleigh irving ltd - limonene, (+)- (unii: gfd7c86q1w) (limonene, (+)- - unii:gfd7c86q1w), iodoform (unii: kxi2j76489) (iodoform - unii:kxi2j76489) - limonene, (+)- 0.84 g in 1 ml

Israel - English - Ministry of Health

amgen europe b.v. - talimogene laherparepvec - solution for injection - talimogene laherparepvec 10^8 pfu / 1 ml - talimogene laherparepvec - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

Israel - English - Ministry of Health

amgen europe b.v. - talimogene laherparepvec - solution for injection - talimogene laherparepvec 10^6 pfu / 1 ml - talimogene laherparepvec - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

lifestyle logic pty limited - d-limonene - aerosol - d-limonene perfume active 58.0 g/l - household insecticide - indoor area | outdoor area - general - ant | cockroach | flea | mosquito larva | argentine ant | ctenocephalides spp. | ground fleas | large cockroach | ochlerotatus vigilax | pharaoh ant | small cockroach

European Union - English - EMA (European Medicines Agency)

amgen europe b.v. - talimogene laherparepvec - melanoma - antineoplastic agents - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zeolite australia pty limited - d-limonene - other liquids to be applied undiluted - d-limonene perfume active 16.8 g/l - herbicide